This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Treatment-related toxicity and outcomes in older versus younger patients with esophageal cancer treated with neoadjuvant chemoradiation
J Geriatr Oncol. 2020 May;11(4) :668-674
PMID: 31257165 PMCID: PMC7751616 URL: https://www.ncbi.nlm.nih.gov/pubmed/31257165
AbstractBackground: Neoadjuvant chemoradiation (nCRT) followed by esophagectomy is the standard treatment for locally advanced esophageal cancer. Older patients are often felt to be poor candidates for nCRT. Limited data is available to guide the use of nCRT in this population. Methods: A retrospective review of patients treated at a tertiary cancer center between 2002 and 2014 was conducted grouping patients by age (>= 65 or <y 65) for evaluation of differences in toxicity and outcomes. Evaluation of pre-treatment platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) was also performed. Univariate (UVA) and multivariate analyses (MVA) determined associations between age, toxicities and outcomes. The Kaplan-Meier method (KM) assessed overall survival (OS) and relapse free survival (RFS). Results: 125 patientswere identified for this study (67 aging <65, and 58 >= 65). In theUVA, advanced agewas only associatedwith increased hematologic toxicity (p = .04). After adjusting for covariates in theMVA, therewere no significant differences in toxicity between older and younger patients. There were also no differences between overall survival and relapse free survival between age groups. Increased pre-treatment NLR was strongly correlated with advanced age (p =.01), increased hospitalizations (p =.04), and decreased RFS (p =.002). Conclusions: Older patients who underwent nCRT followed by esophagectomy had similar toxicities and outcomes as younger patients suggesting that nCRT before esophagectomy is safe in select older adults with esophageal cancer. PLR and NLR may serve as prognostic markers of aging, toxicity, and outcomes. Further research is warranted to optimize the therapy of older patients with this disease. (C) 2019 Elsevier Ltd. All rights reserved.
NotesJ Geriatr Oncol. 2020 May;11(4):668-674. doi: 10.1016/j.jgo.2019.06.014. Epub 2019 Jun 28.